Cantor Fitzgerald set a $40.00 price target on Heron Therapeutics (NASDAQ:HRTX) in a report released on Sunday. The brokerage currently has a buy rating on the biotechnology company’s stock.
HRTX has been the topic of several other reports. BidaskClub raised Heron Therapeutics from a hold rating to a buy rating in a research note on Saturday, January 20th. Mizuho reaffirmed a buy rating and set a $28.00 target price on shares of Heron Therapeutics in a research note on Tuesday, January 16th. ValuEngine raised Heron Therapeutics from a sell rating to a hold rating in a research note on Sunday, December 31st. Zacks Investment Research cut Heron Therapeutics from a buy rating to a hold rating in a research note on Wednesday, January 10th. Finally, Lake Street Capital set a $42.00 target price on Heron Therapeutics and gave the stock a buy rating in a report on Friday, February 16th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $35.92.
Shares of NASDAQ HRTX opened at $31.69 on Friday. Heron Therapeutics has a 1-year low of $12.70 and a 1-year high of $32.70. The company has a market cap of $2,213.04, a price-to-earnings ratio of 8.68 and a beta of 1.86.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.29). Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. The company had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9.00 million. equities analysts predict that Heron Therapeutics will post -2.48 EPS for the current fiscal year.
In other Heron Therapeutics news, VP Kimberly Manhard sold 18,000 shares of the stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $30.00, for a total transaction of $540,000.00. Following the sale, the vice president now directly owns 18,000 shares of the company’s stock, valued at approximately $540,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Barry D. Quart sold 100,000 shares of the stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $24.75, for a total value of $2,475,000.00. Following the sale, the chief executive officer now directly owns 167,993 shares in the company, valued at $4,157,826.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 218,000 shares of company stock valued at $5,990,000. Company insiders own 19.93% of the company’s stock.
Several large investors have recently bought and sold shares of the company. J. Goldman & Co LP purchased a new position in Heron Therapeutics in the 4th quarter valued at about $1,181,000. MetLife Investment Advisors LLC purchased a new position in Heron Therapeutics in the 4th quarter valued at about $399,000. Jane Street Group LLC lifted its stake in Heron Therapeutics by 36.3% in the 4th quarter. Jane Street Group LLC now owns 18,806 shares of the biotechnology company’s stock valued at $340,000 after buying an additional 5,006 shares in the last quarter. Crestline Management LP lifted its stake in Heron Therapeutics by 190.2% in the 4th quarter. Crestline Management LP now owns 116,290 shares of the biotechnology company’s stock valued at $2,105,000 after buying an additional 76,212 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new position in Heron Therapeutics in the 4th quarter valued at about $231,000. Hedge funds and other institutional investors own 97.38% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics (HRTX) Given a $40.00 Price Target by Cantor Fitzgerald Analysts” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/23/heron-therapeutics-hrtx-given-a-40-00-price-target-by-cantor-fitzgerald-analysts-2.html.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.